- Home
- MITT vs URGN Comparison
MITT vs URGN Comparison
Compare MITT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITT
- URGN
- Stock Information
- Founded
- MITT 2011
- URGN 2004
- Country
- MITT United States
- URGN United States
- Employees
- MITT N/A
- URGN N/A
- Industry
- MITT Real Estate Investment Trusts
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MITT Real Estate
- URGN Health Care
- Exchange
- MITT Nasdaq
- URGN Nasdaq
- Market Cap
- MITT 204.8M
- URGN 181.2M
- IPO Year
- MITT 2011
- URGN 2017
- Fundamental
- Price
- MITT $7.67
- URGN $13.84
- Analyst Decision
- MITT Strong Buy
- URGN Strong Buy
- Analyst Count
- MITT 4
- URGN 8
- Target Price
- MITT $8.50
- URGN $29.00
- AVG Volume (30 Days)
- MITT 225.4K
- URGN 4.3M
- Earning Date
- MITT 08-01-2025
- URGN 08-12-2025
- Dividend Yield
- MITT 10.46%
- URGN N/A
- EPS Growth
- MITT N/A
- URGN N/A
- EPS
- MITT 0.89
- URGN N/A
- Revenue
- MITT $79,955,000.00
- URGN $91,871,000.00
- Revenue This Year
- MITT N/A
- URGN $36.65
- Revenue Next Year
- MITT $9.01
- URGN $88.35
- P/E Ratio
- MITT $8.63
- URGN N/A
- Revenue Growth
- MITT 13.91
- URGN 8.98
- 52 Week Low
- MITT $5.63
- URGN $3.42
- 52 Week High
- MITT $7.95
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- MITT 55.33
- URGN 64.90
- Support Level
- MITT $7.55
- URGN $13.26
- Resistance Level
- MITT $7.90
- URGN $13.94
- Average True Range (ATR)
- MITT 0.20
- URGN 0.91
- MACD
- MITT -0.02
- URGN -0.08
- Stochastic Oscillator
- MITT 61.64
- URGN 44.44
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.